[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100629215":3},{"organization":4,"armGroups":7,"interventions":15,"overallOfficials":10,"centralContacts":30,"locations":36,"responsibleParty":62,"collaborators":10,"id":66,"slug":67,"hasResults":68,"nctId":69,"briefTitle":70,"officialTitle":70,"acronym":10,"eligibilityCriteria":71,"healthyVolunteers":68,"sex":72,"minAge":73,"maxAge":10,"enrollmentInfo":74,"targetDuration":10,"studyType":77,"phases":78,"briefSummary":80,"conditions":81,"keywords":10,"overallStatus":39,"whyStopped":10,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":87,"completionDateStruct":89,"leadSponsor":91,"locationsCount":92},{"fullName":5,"class":6},"Fudan University","OTHER",[8],{"label":9,"type":6,"description":10,"interventionNames":11},"TROP2 ADC",null,[12,13,14],"Drug: Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan","Diagnostic Test: 68Ga-TROP2 PET\u002FCT Imaging","Diagnostic Test: 18F-FDG PET Imaging",[16,21,26],{"type":17,"name":18,"description":19,"armGroupLabels":20,"otherNames":10},"DRUG","Sacituzumab Govitecan、Datopotamab deruxtecan、Sacituzumab tirumotecan","TROP2-targeted antibody-drug conjugate administered according to standard clinical dosing schedule until disease progression or unacceptable toxicity.",[9],{"type":22,"name":23,"description":24,"armGroupLabels":25,"otherNames":10},"DIAGNOSTIC_TEST","68Ga-TROP2 PET\u002FCT Imaging","Whole-body PET imaging using 68Ga-labeled TROP2-targeting tracer to assess in vivo TROP2 expression prior to TROP2 ADC treatment initiation.",[9],{"type":22,"name":27,"description":28,"armGroupLabels":29,"otherNames":10},"18F-FDG PET Imaging","Standard 18F-FDG PET imaging performed prior to TROP2 ADC treatment to assess tumor metabolic activity.",[9],[31],{"name":32,"role":33,"phone":34,"phoneExt":10,"email":35},"Biyun Wang","CONTACT","021-64175590","wangbiyun0107@hotmail.com",[37,54],{"facility":38,"status":39,"city":40,"state":41,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"Fudan University Shanghai Cancer Center","RECRUITING","Shanghai","Shanghai Municipality","200032","China","CN",{"type":46,"coordinates":47},"Point",[48,49],121.45806,31.22222,{"lat":49,"lon":48},[52],{"name":53,"role":33,"phone":34,"phoneExt":10,"email":35},"Biyun wang",{"facility":38,"status":55,"city":40,"state":10,"zip":42,"country":43,"countryCode":44,"cosmosGeoPoint":56,"geoPoint":58,"contacts":59},"NOT_YET_RECRUITING",{"type":46,"coordinates":57},[48,49],{"lat":49,"lon":48},[60],{"name":32,"role":33,"phone":61,"phoneExt":10,"email":35},"18017312387",{"type":63,"investigatorFullName":64,"investigatorTitle":65,"investigatorAffiliation":5,"oldNameTitle":10,"oldOrganization":10},"PRINCIPAL_INVESTIGATOR","Biyun Wang, MD","Professor","100629215","phase-2-study-on-using-trop2-pet-and-18f-fdg-pet-to-predict-the-efficacy-of-anti-trop2-adc-treatment-in-advanced-breast-cancer-100629215",false,"NCT07471776","Study on Using TROP2-PET and 18F-FDG PET to Predict the Efficacy of Anti TROP2 ADC Treatment in Advanced Breast Cancer","Inclusion Criteria:\n\n* Patients diagnosed with advanced\u002Fmetastatic HER2-negative breast cancer with confirmed metastatic disease, regardless of being de novo diagnosed or progressed from a non-metastatic stage.\n* Patients who are planned to receive anti-TROP2 antibody-drug conjugate (ADC) therapy (e.g., sacituzumab govitecan or datopotamab deruxtecan) as part of routine clinical care.\n* Patients who will undergo protocol-defined \\^68Ga-TROP2 PET\u002FCT and \\^18F-FDG PET\u002FCT during the study (baseline imaging, with repeat imaging per protocol if applicable).\n* Adult patients (≥18 years) who are able to provide informed consent and comply with study procedures.\n\nExclusion Criteria:\n\n* Patients with incomplete medical records or inability to complete the required imaging assessments.\n* Patients with prior exposure to an anti-TROP2 ADC.\n* Patients with known contraindications to PET\u002FCT or known allergy to \\^18F-FDG or the \\^68Ga-TROP2 tracer (or their components).\n* Patients who are pregnant or breastfeeding.\n* Patients diagnosed with secondary primary tumors (other active malignancies), as determined by the investigator.","ALL","18 Years",{"count":75,"type":76},45,"ESTIMATED","INTERVENTIONAL",[79],"PHASE2","This study aims to evaluate whether \\^68Ga-TROP2 PET\u002FCT, combined with \\^18F-FDG PET\u002FCT, can predict the efficacy of anti-TROP2 antibody-drug conjugates in patients with advanced HER2-negative breast cancer. Baseline and dynamic imaging parameters will be used to develop prediction models (primary endpoint: AUC), and their associations with clinical outcomes and tumor TROP2 status will be explored.",[82],"Metastatic Breast Cancer ( HER2 Negative)","2026-03-10",{"date":85,"type":86},"2026-03-13","ACTUAL",{"date":88,"type":86},"2026-03-11",{"date":90,"type":76},"2029-03-11",{"name":5,"class":6},2]